Stem definition | Drug id | CAS RN |
---|---|---|
psychoactive | 1613 | 1977-10-2 |
Dose | Unit | Route |
---|---|---|
9.10 | mg | Inhal.powder |
0.10 | g | O |
Property | Value | Reference |
---|---|---|
BA (Bioavailability) | 30 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 25, 1975 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Coma | 355.14 | 34.87 | 139 | 3569 | 56740 | 50544676 |
Poisoning deliberate | 350.56 | 34.87 | 87 | 3621 | 7825 | 50593591 |
Neuroleptic malignant syndrome | 220.96 | 34.87 | 65 | 3643 | 11065 | 50590351 |
Extrapyramidal disorder | 150.13 | 34.87 | 49 | 3659 | 11721 | 50589695 |
Hepatocellular injury | 146.01 | 34.87 | 59 | 3649 | 25888 | 50575528 |
Cholestasis | 123.36 | 34.87 | 52 | 3656 | 25349 | 50576067 |
Oculogyric crisis | 111.94 | 34.87 | 25 | 3683 | 1412 | 50600004 |
Somnolence | 110.60 | 34.87 | 91 | 3617 | 154894 | 50446522 |
Intestinal obstruction | 92.55 | 34.87 | 43 | 3665 | 26340 | 50575076 |
Toxicity to various agents | 84.23 | 34.87 | 90 | 3618 | 212409 | 50389007 |
Pneumonia aspiration | 71.49 | 34.87 | 38 | 3670 | 30966 | 50570450 |
Benzodiazepine drug level increased | 69.33 | 34.87 | 12 | 3696 | 175 | 50601241 |
Altered state of consciousness | 65.49 | 34.87 | 32 | 3676 | 21878 | 50579538 |
Galactorrhoea | 61.95 | 34.87 | 19 | 3689 | 3704 | 50597712 |
Catatonia | 61.88 | 34.87 | 19 | 3689 | 3717 | 50597699 |
Intentional overdose | 60.34 | 34.87 | 44 | 3664 | 62460 | 50538956 |
Hypothermia | 59.61 | 34.87 | 25 | 3683 | 11991 | 50589425 |
Hyperprolactinaemia | 59.52 | 34.87 | 18 | 3690 | 3347 | 50598069 |
Brain death | 58.44 | 34.87 | 17 | 3691 | 2766 | 50598650 |
Faecaloma | 57.21 | 34.87 | 21 | 3687 | 7087 | 50594329 |
Tachycardia | 55.64 | 34.87 | 51 | 3657 | 99712 | 50501704 |
Antipsychotic drug level above therapeutic | 49.77 | 34.87 | 12 | 3696 | 947 | 50600469 |
Hypotension | 48.52 | 34.87 | 72 | 3636 | 235397 | 50366019 |
Hyperthermia | 48.44 | 34.87 | 19 | 3689 | 7677 | 50593739 |
Miosis | 48.42 | 34.87 | 18 | 3690 | 6292 | 50595124 |
Rhabdomyolysis | 48.26 | 34.87 | 32 | 3676 | 38995 | 50562421 |
Intestinal pseudo-obstruction | 47.30 | 34.87 | 11 | 3697 | 743 | 50600673 |
Dystonia | 46.70 | 34.87 | 21 | 3687 | 11905 | 50589511 |
Cardio-respiratory arrest | 45.45 | 34.87 | 35 | 3673 | 53857 | 50547559 |
Overdose | 44.30 | 34.87 | 45 | 3663 | 99682 | 50501734 |
Suicide attempt | 40.16 | 34.87 | 32 | 3676 | 51700 | 50549716 |
Amenorrhoea | 39.90 | 34.87 | 17 | 3691 | 8467 | 50592949 |
Asphyxia | 39.88 | 34.87 | 15 | 3693 | 5412 | 50596004 |
Newborn persistent pulmonary hypertension | 38.21 | 34.87 | 7 | 3701 | 143 | 50601273 |
Akathisia | 37.09 | 34.87 | 16 | 3692 | 8213 | 50593203 |
Anterograde amnesia | 35.10 | 34.87 | 8 | 3700 | 494 | 50600922 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Coma | 290.06 | 34.31 | 147 | 5871 | 39303 | 29529206 |
Therapeutic product effect variable | 259.36 | 34.31 | 63 | 5955 | 1814 | 29566695 |
Antipsychotic drug level below therapeutic | 256.21 | 34.31 | 63 | 5955 | 1911 | 29566598 |
Disinhibition | 243.61 | 34.31 | 64 | 5954 | 2543 | 29565966 |
Akathisia | 239.02 | 34.31 | 78 | 5940 | 6664 | 29561845 |
Obsessive-compulsive disorder | 229.39 | 34.31 | 69 | 5949 | 4507 | 29564002 |
Euphoric mood | 200.48 | 34.31 | 63 | 5955 | 4762 | 29563747 |
Increased appetite | 186.33 | 34.31 | 63 | 5955 | 6001 | 29562508 |
Neuroleptic malignant syndrome | 160.17 | 34.31 | 74 | 5944 | 16074 | 29552435 |
Suicide attempt | 130.38 | 34.31 | 83 | 5935 | 34027 | 29534482 |
Hepatocellular injury | 129.61 | 34.31 | 70 | 5948 | 21173 | 29547336 |
Extrapyramidal disorder | 121.16 | 34.31 | 54 | 5964 | 10777 | 29557732 |
Wrong patient received product | 112.54 | 34.31 | 34 | 5984 | 2248 | 29566261 |
Rhabdomyolysis | 105.48 | 34.31 | 92 | 5926 | 60716 | 29507793 |
Poisoning deliberate | 102.70 | 34.31 | 40 | 5978 | 5691 | 29562818 |
Therapeutic product effect incomplete | 101.25 | 34.31 | 75 | 5943 | 39230 | 29529279 |
Miosis | 99.50 | 34.31 | 43 | 5975 | 7966 | 29560543 |
Dyslipidaemia | 86.79 | 34.31 | 36 | 5982 | 6025 | 29562484 |
Obesity | 81.82 | 34.31 | 40 | 5978 | 9823 | 29558686 |
Leukopenia | 77.07 | 34.31 | 74 | 5944 | 55129 | 29513380 |
Leukaemia | 76.88 | 34.31 | 29 | 5989 | 3781 | 29564728 |
Prescribed overdose | 74.38 | 34.31 | 36 | 5982 | 8647 | 29559862 |
Product use in unapproved indication | 72.96 | 34.31 | 89 | 5929 | 86786 | 29481723 |
Hypothermia | 69.31 | 34.31 | 35 | 5983 | 9204 | 29559305 |
Somnolence | 68.96 | 34.31 | 90 | 5928 | 93865 | 29474644 |
Toxicity to various agents | 65.14 | 34.31 | 122 | 5896 | 173539 | 29394970 |
Weight increased | 63.46 | 34.31 | 78 | 5940 | 76589 | 29491920 |
Colitis ischaemic | 61.80 | 34.31 | 28 | 5990 | 5795 | 29562714 |
Hyperleukocytosis | 58.22 | 34.31 | 19 | 5999 | 1616 | 29566893 |
Faecaloma | 53.61 | 34.31 | 23 | 5995 | 4179 | 29564330 |
Subileus | 51.42 | 34.31 | 20 | 5998 | 2830 | 29565679 |
Pneumonia aspiration | 50.75 | 34.31 | 49 | 5969 | 36688 | 29531821 |
Fatigue | 46.98 | 34.31 | 5 | 6013 | 316816 | 29251693 |
Bradypnoea | 44.06 | 34.31 | 17 | 6001 | 2354 | 29566155 |
Blood creatine phosphokinase increased | 43.06 | 34.31 | 47 | 5971 | 40597 | 29527912 |
Necrotising colitis | 41.16 | 34.31 | 13 | 6005 | 995 | 29567514 |
Congestive cardiomyopathy | 40.80 | 34.31 | 22 | 5996 | 6608 | 29561901 |
Tachycardia | 37.75 | 34.31 | 59 | 5959 | 72351 | 29496158 |
Mydriasis | 36.91 | 34.31 | 20 | 5998 | 6065 | 29562444 |
Electrocardiogram QT prolonged | 36.90 | 34.31 | 41 | 5977 | 36096 | 29532413 |
Schizoaffective disorder | 36.10 | 34.31 | 12 | 6006 | 1080 | 29567429 |
Hyperthermia | 36.08 | 34.31 | 23 | 5995 | 9407 | 29559102 |
Compensatory sweating | 35.35 | 34.31 | 6 | 6012 | 24 | 29568485 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Coma | 640.37 | 32.90 | 286 | 8449 | 87329 | 64402668 |
Poisoning deliberate | 423.24 | 32.90 | 129 | 8606 | 13329 | 64476668 |
Neuroleptic malignant syndrome | 366.97 | 32.90 | 135 | 8600 | 24861 | 64465136 |
Extrapyramidal disorder | 277.31 | 32.90 | 103 | 8632 | 19449 | 64470548 |
Hepatocellular injury | 268.03 | 32.90 | 128 | 8607 | 45107 | 64444890 |
Somnolence | 186.58 | 32.90 | 180 | 8555 | 203465 | 64286532 |
Rhabdomyolysis | 172.13 | 32.90 | 123 | 8612 | 91603 | 64398394 |
Miosis | 156.02 | 32.90 | 61 | 8674 | 13205 | 64476792 |
Pneumonia aspiration | 131.11 | 32.90 | 88 | 8647 | 59183 | 64430814 |
Hypothermia | 129.19 | 32.90 | 60 | 8675 | 19796 | 64470201 |
Intestinal obstruction | 113.18 | 32.90 | 67 | 8668 | 36219 | 64453778 |
Faecaloma | 111.80 | 32.90 | 44 | 8691 | 9684 | 64480313 |
Akathisia | 107.99 | 32.90 | 45 | 8690 | 11465 | 64478532 |
Wrong patient received product | 105.21 | 32.90 | 33 | 8702 | 3729 | 64486268 |
Cholestasis | 90.60 | 32.90 | 63 | 8672 | 44809 | 64445188 |
Catatonia | 89.43 | 32.90 | 35 | 8700 | 7585 | 64482412 |
Tachycardia | 88.44 | 32.90 | 105 | 8630 | 149474 | 64340523 |
Hyperthermia | 85.90 | 32.90 | 42 | 8693 | 15508 | 64474489 |
Subileus | 84.59 | 32.90 | 30 | 8705 | 4947 | 64485050 |
Toxicity to various agents | 82.13 | 32.90 | 163 | 8572 | 363350 | 64126647 |
Altered state of consciousness | 78.35 | 32.90 | 54 | 8681 | 37848 | 64452149 |
Oculogyric crisis | 78.28 | 32.90 | 24 | 8711 | 2514 | 64487483 |
Blood creatine phosphokinase increased | 71.54 | 32.90 | 61 | 8674 | 58497 | 64431500 |
Necrotising colitis | 71.20 | 32.90 | 18 | 8717 | 926 | 64489071 |
Fatigue | 71.10 | 32.90 | 9 | 8726 | 748721 | 63741276 |
Asphyxia | 68.77 | 32.90 | 31 | 8704 | 9535 | 64480462 |
Cardio-respiratory arrest | 68.13 | 32.90 | 75 | 8660 | 98318 | 64391679 |
Bladder dilatation | 67.83 | 32.90 | 20 | 8715 | 1834 | 64488163 |
Suicide attempt | 67.09 | 32.90 | 64 | 8671 | 70943 | 64419054 |
Hyperleukocytosis | 65.94 | 32.90 | 20 | 8715 | 2020 | 64487977 |
Benzodiazepine drug level increased | 59.86 | 32.90 | 12 | 8723 | 211 | 64489786 |
Bradypnoea | 58.09 | 32.90 | 23 | 8712 | 5136 | 64484861 |
Antipsychotic drug level below therapeutic | 55.98 | 32.90 | 15 | 8720 | 970 | 64489027 |
Galactorrhoea | 53.18 | 32.90 | 19 | 8716 | 3200 | 64486797 |
Distal intestinal obstruction syndrome | 52.27 | 32.90 | 13 | 8722 | 625 | 64489372 |
Faecal vomiting | 50.74 | 32.90 | 14 | 8721 | 1011 | 64488986 |
Colitis ischaemic | 50.44 | 32.90 | 28 | 8707 | 13386 | 64476611 |
Respiratory acidosis | 49.62 | 32.90 | 25 | 8710 | 9830 | 64480167 |
Electrocardiogram QT prolonged | 48.92 | 32.90 | 57 | 8678 | 79391 | 64410606 |
Therapeutic product effect variable | 48.39 | 32.90 | 15 | 8720 | 1629 | 64488368 |
Disinhibition | 47.74 | 32.90 | 16 | 8719 | 2227 | 64487770 |
Pain | 47.13 | 32.90 | 9 | 8726 | 553502 | 63936495 |
Confusional state | 47.12 | 32.90 | 107 | 8628 | 261037 | 64228960 |
Housebound | 45.86 | 32.90 | 11 | 8724 | 454 | 64489543 |
Agitation | 45.63 | 32.90 | 58 | 8677 | 88309 | 64401688 |
Congestive cardiomyopathy | 45.61 | 32.90 | 24 | 8711 | 10320 | 64479677 |
Brain death | 45.57 | 32.90 | 19 | 8716 | 4842 | 64485155 |
Dystonia | 44.05 | 32.90 | 29 | 8706 | 18836 | 64471161 |
Product use in unapproved indication | 41.91 | 32.90 | 81 | 8654 | 176537 | 64313460 |
Intentional overdose | 41.72 | 32.90 | 56 | 8679 | 89888 | 64400109 |
Dyspnoea | 40.04 | 32.90 | 24 | 8711 | 718650 | 63771347 |
Antipsychotic drug level above therapeutic | 38.52 | 32.90 | 13 | 8722 | 1848 | 64488149 |
Hyperprolactinaemia | 38.48 | 32.90 | 16 | 8719 | 4049 | 64485948 |
Psychotic disorder | 38.14 | 32.90 | 34 | 8701 | 34544 | 64455453 |
Intestinal ischaemia | 37.75 | 32.90 | 22 | 8713 | 11527 | 64478470 |
Urinary retention | 36.63 | 32.90 | 39 | 8696 | 49162 | 64440835 |
Diabetic hyperosmolar coma | 36.46 | 32.90 | 10 | 8725 | 706 | 64489291 |
Camptocormia | 35.43 | 32.90 | 9 | 8726 | 472 | 64489525 |
Compensatory sweating | 34.61 | 32.90 | 6 | 8729 | 45 | 64489952 |
Choking | 34.25 | 32.90 | 20 | 8715 | 10518 | 64479479 |
Euphoric mood | 34.00 | 32.90 | 17 | 8718 | 6574 | 64483423 |
Arthralgia | 33.99 | 32.90 | 9 | 8726 | 442251 | 64047746 |
Intestinal pseudo-obstruction | 33.77 | 32.90 | 12 | 8723 | 1988 | 64488009 |
Psychotic symptom | 32.99 | 32.90 | 12 | 8723 | 2126 | 64487871 |
None
Source | Code | Description |
---|---|---|
ATC | N05AH01 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Diazepines, oxazepines, thiazepines and oxepines |
MeSH PA | D014150 | Antipsychotic Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018492 | Dopamine Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D014149 | Tranquilizing Agents |
CHEBI has role | CHEBI:35476 | neuroleptics |
CHEBI has role | CHEBI:48561 | dopaminergic antagonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Bipolar disorder | indication | 13746004 | DOID:3312 |
Schizophrenia | indication | 58214004 | DOID:5419 |
Alcoholism | contraindication | 7200002 | |
Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
Senile dementia | contraindication | 15662003 | |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Tardive dyskinesia | contraindication | 102449007 | |
Seizure disorder | contraindication | 128613002 | |
Hyperprolactinemia | contraindication | 237662005 | DOID:12700 |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Retention of urine | contraindication | 267064002 | |
Coma | contraindication | 371632003 | |
Carcinoma of female breast | contraindication | 447782002 | |
Pigmentary Retinopathy | contraindication | ||
Drug Induced CNS Depression | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.59 | Basic |
pKa2 | 3.24 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 7.68 | CHEMBL | CHEMBL | |||
5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 8.62 | CHEMBL | CHEMBL | |||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.82 | PDSP | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.24 | PDSP | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.61 | PDSP | |||||
5-hydroxytryptamine receptor 2C | GPCR | ANTAGONIST | Ki | 8 | IUPHAR | ||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 7.82 | CHEMBL | |||||
Alpha-1A adrenergic receptor | GPCR | Ki | 7.51 | PDSP | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 6.97 | PDSP | |||||
D(3) dopamine receptor | GPCR | ANTAGONIST | IC50 | 7.66 | CHEMBL | ||||
D(1B) dopamine receptor | GPCR | Ki | 7.13 | PDSP | |||||
Histamine H1 receptor | GPCR | ANTAGONIST | Ki | 8.20 | IUPHAR | ||||
Histamine H2 receptor | GPCR | Ki | 6.68 | PDSP | |||||
Histamine H4 receptor | GPCR | Ki | 5.30 | PDSP | |||||
Muscarinic acetylcholine receptor M1 | GPCR | IC50 | 5.26 | CHEMBL | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 6.38 | PDSP | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 6.91 | PDSP | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.09 | PDSP | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 6.83 | PDSP | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 6.41 | PDSP | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 7.10 | PDSP | |||||
D(4) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.31 | CHEMBL | ||||
5-hydroxytryptamine receptor 3A | Ion channel | Ki | 6.72 | PDSP | |||||
Alpha-1B adrenergic receptor | GPCR | Ki | 7.28 | PDSP | |||||
5-hydroxytryptamine receptor 5A | GPCR | Ki | 6.11 | PDSP | |||||
5-hydroxytryptamine receptor 1E | GPCR | Ki | 5.85 | PDSP | |||||
Potassium channel subfamily K member 2 | Ion channel | IC50 | 4.70 | CHEMBL | |||||
Potassium channel subfamily T member 1 | Ion channel | ACTIVATOR | EC50 | 5.36 | IUPHAR | ||||
5-hydroxytryptamine receptor 1D | GPCR | Ki | 5.46 | PDSP | |||||
D(1A) dopamine receptor | GPCR | Ki | 7.27 | PDSP | |||||
D(2) dopamine receptor | GPCR | Ki | 7.68 | CHEMBL | |||||
5-hydroxytryptamine receptor 2A | GPCR | IC50 | 8.22 | CHEMBL | |||||
5-hydroxytryptamine receptor 7 | GPCR | Ki | 7.37 | CHEMBL | |||||
5-hydroxytryptamine receptor 2C | GPCR | IC50 | 6 | CHEMBL | |||||
Histamine H1 receptor | GPCR | IC50 | 6 | CHEMBL | |||||
5-hydroxytryptamine receptor 6 | GPCR | ANTAGONIST | Ki | 7.80 | IUPHAR | ||||
Adrenergic receptor alpha-1 | GPCR | IC50 | 7.74 | CHEMBL |
ID | Source |
---|---|
4019805 | VUID |
N0000147894 | NUI |
D00794 | KEGG_DRUG |
27833-64-3 | SECONDARY_CAS_RN |
54810-23-0 | SECONDARY_CAS_RN |
4017917 | VANDF |
4017918 | VANDF |
4019805 | VANDF |
C0024056 | UMLSCUI |
CHEBI:50841 | CHEBI |
CHEMBL831 | ChEMBL_ID |
CHEMBL1201155 | ChEMBL_ID |
DB00408 | DRUGBANK_ID |
D008152 | MESH_DESCRIPTOR_UI |
3964 | PUBCHEM_CID |
205 | IUPHAR_LIGAND_ID |
2610 | INN_ID |
LER583670J | UNII |
1364415 | RXNORM |
1308 | MMSL |
1346 | MMSL |
196711 | MMSL |
29026 | MMSL |
4999 | MMSL |
5000 | MMSL |
d00897 | MMSL |
001522 | NDDF |
001523 | NDDF |
001524 | NDDF |
1971003 | SNOMEDCT_US |
30745005 | SNOMEDCT_US |
372789006 | SNOMEDCT_US |
59270007 | SNOMEDCT_US |
CHEMBL1201060 | ChEMBL_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1394 | CAPSULE | 5 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1395 | CAPSULE | 10 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1396 | CAPSULE | 25 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1397 | CAPSULE | 50 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-0369 | CAPSULE | 5 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-0370 | CAPSULE | 10 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-0371 | CAPSULE | 25 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-0372 | CAPSULE | 50 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-585 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-586 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-587 | TABLET | 25 mg | ORAL | ANDA | 19 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-588 | TABLET | 50 mg | ORAL | ANDA | 19 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-1397 | CAPSULE | 50 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35573-436 | CAPSULE | 5 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35573-437 | CAPSULE | 10 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35573-438 | CAPSULE | 25 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35573-439 | CAPSULE | 50 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4701 | CAPSULE | 10 mg | ORAL | ANDA | 21 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4701 | CAPSULE | 10 mg | ORAL | ANDA | 21 sections |
Adasuve | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51097-001 | AEROSOL, POWDER | 10 mg | RESPIRATORY (INHALATION) | NDA | 31 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64850-890 | CAPSULE | 5 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64850-891 | CAPSULE | 10 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64850-892 | CAPSULE | 25 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64850-893 | CAPSULE | 50 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2875 | CAPSULE | 5 mg | ORAL | ANDA | 18 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-0283 | CAPSULE | 10 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-0283 | CAPSULE | 10 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-0346 | CAPSULE | 5 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-0346 | CAPSULE | 5 mg | ORAL | ANDA | 20 sections |
Loxapine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-0347 | CAPSULE | 25 mg | ORAL | ANDA | 20 sections |